Batches of the world’s first vaccine against the hepatitis E virus began rolling out of a Chinese factory, promising to stem a disease that every year infects about 20 million people and claims 70,000 lives. The vaccine is being hailed as a victory for an unusual public–private partnership that could set a precedent in China’s burgeoning biotechnology sector, and help to deliver other vaccines for diseases overlooked in the West.